8-K: Aytu BioPharma Secures Exclusive U.S. Commercialization Rights for FDA-Approved Antidepressant EXXUA

Aytu BioPharma has entered into an exclusive agreement with Fabre-Kramer Holdings, Inc. to commercialize EXXUA, a first-in-class, FDA-approved treatment for Major Depressive Disorder, targeting the substantial $22 billion U.S. prescription MDD market.

Summary

• Aytu BioPharma, Inc. has signed an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. for EXXUA (gepirone) extended-release tablets in the United States.
• EXXUA is an FDA-approved, first-in-class selective serotonin 5HT1a receptor agonist indicated for the treatment of Major Depressive Disorder (MDD) in adults.
• The U.S. prescription MDD market is valued at over $22 billion, with over 21 million Americans affected by MDD and over 340 million antidepressant prescriptions written in 2024.
• Aytu anticipates launching EXXUA in the fourth calendar quarter of 2025 through its commercial team.
• As consideration, Aytu made an upfront cash payment of $3,000,000 to Fabre-Kramer.
• A second payment of $3,000,000 is due within 45 days of the one-year anniversary of the first physical sale, potentially increasing to $5,000,000 if first-year net sales meet or exceed $35 million.
• Aytu will also pay sales milestones ranging from $5,000,000 to over $100,000,000 per year based on net sales exceeding $100,000,000, and 10% of net sales exceeding $1 billion.
• Royalty fees will be initially 28% of net sales, increasing to 39% if net sales exceed $300 million in any year until a reduced royalty trigger; after reaching such trigger, rates will be 24.5% and increasing to 35.5% if net sales exceed $300 million.
• A supply price of 3% of net sales less cost of goods sold will be paid, increasing to 4% if annual net sales exceed $300 million.
• The transaction is funded by cash on hand and a financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders.

Sentiment

Score: 9

Explanation: The document announces a highly significant strategic acquisition of an FDA-approved, first-in-class drug (EXXUA) for a large and underserved market (MDD). The product has a differentiated profile addressing key unmet needs (sexual side effects). The deal is well-financed by institutional investors, and management views it as transformative and a centerpiece of future growth. The financial terms, while substantial, reflect the potential market opportunity. The overall tone and content are overwhelmingly positive, indicating a strong growth catalyst for the company.

Positives

• Secured exclusive U.S. commercialization rights for EXXUA, an FDA-approved, first-in-class antidepressant for Major Depressive Disorder (MDD).
• EXXUA offers a novel mechanism of action and a differentiated clinical profile, notably with an incidence of sexual side effects comparable to placebo, addressing a significant unmet need in MDD treatment.
• The U.S. prescription MDD market is substantial, valued at over $22 billion, providing a significant commercial opportunity for EXXUA.
• EXXUA has been extensively studied in over 5,000 patients, demonstrating significant improvement in depression symptoms.
• The acquisition aligns with Aytu's strategic pivot to focus on differentiated, branded CNS products, making EXXUA a centerpiece of its commercial efforts.
• The transaction is financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder and management, indicating strong investor confidence.
• EXXUA does not carry label warnings about the risk of sexual dysfunction, unlike many other antidepressants, and exhibits no significant adverse effects on weight, blood pressure, heart rate, or liver function.

Negatives

• The agreement involves substantial future financial commitments, including an upfront payment of $3,000,000, a potential second payment of up to $5,000,000, sales-based milestone payments ranging from $5,000,000 to over $100,000,000 annually, and significant royalty fees (initially 28% to 39% of net sales).
• The success of EXXUA is dependent on market acceptance and Aytu's ability to effectively commercialize the product in a competitive market.

Risks

• The Company's overall financial and operational performance may be adversely affected.
• Potential adverse changes to the Company's financial position, business, results of operations, strategy, and plans.
• Changes in capital markets and the Company's ability to finance operations as expected.
• Risks related to gaining market acceptance of EXXUA.
• Risks associated with partners performing their required activities under the agreement.
• Regulatory and compliance challenges related to EXXUA.
• Future events under current and potential future collaborations.
• The agreement can be terminated by either party for a material default or breach if not cured within 90 to 120 days.
• Termination is possible if either party withdraws the Product from the market for safety reasons.
• Termination can occur if the FDA materially restricts the indications for EXXUA or if federal or state pricing controls are imposed that would result in obvious or substantial loss of sales.

Future Outlook

Aytu BioPharma anticipates launching EXXUA in the fourth calendar quarter of 2025, positioning it as a major growth catalyst and a centerpiece of the company's commercial efforts. The company believes EXXUA can become a very important treatment option for the over 21 million Americans affected by MDD, addressing significant unmet needs in the over $22 billion U.S. prescription MDD market. The company expects to build significant value for shareholders through this strategic acquisition.

Management Comments

• "We are thrilled to be the exclusive commercialization partner for EXXUA in the United States and to be partnering with Fabre-Kramer Pharmaceuticals on this exciting opportunity. We believe that the licensing of EXXUA represents a transformative milestone for Aytu and a significant advancement for patients suffering from major depressive disorder." Josh Disbrow, CEO of Aytu.
• "Over the past two years, Aytu has undergone a planned, strategic pivot to focus on our core prescription business while seeking to acquire differentiated, branded CNS products that complement our portfolio and focus. We believe that EXXUA is a perfect strategic fit and will be a centerpiece of Aytus commercial efforts going forward considering the significant commercial potential, uniqueness of the product, our sales forces CNS focus and alignment with our proprietary Aytu RxConnect patient access platform." Josh Disbrow, CEO of Aytu.
• "More importantly, given the compelling and novel product profile of EXXUA and the unmet needs of MDD patients, we believe EXXUA can become a very important treatment option for the over 21 million Americans affected by MDD." Josh Disbrow, CEO of Aytu.
• "EXXUA is the first truly selective agonist of the serotonin 1a receptor that has been consistently linked to mediation of mood disorders and suicide risk. Its an important addition to the armamentarium to treat depression." Dr. Stephen Stahl, Professor of Psychiatry, University of California and founder of the Neuroscience Education Institute.
• "We developed EXXUA to address important unmet needs that I witnessed first-hand managing MDD patients for decades as a practicing psychiatrist. While therapeutic advancements have been made, issues such as treatment emergent sexual dysfunction and weight gain persist as problematic side effects of many MDD treatments. We believe EXXUA will be a very important addition to physicians managing the millions of patients with depression in the United States and worldwide." Stephen Kramer, M.D., Co-Founder and Chief Executive Officer of Fabre-Kramer Pharmaceuticals.

Industry Context

The U.S. prescription Major Depressive Disorder (MDD) market is a significant and growing sector, valued at over $22 billion, with over 340 million antidepressant prescriptions written in 2024. Despite the high volume of prescriptions, significant unmet needs persist, particularly concerning the unacceptable side effects associated with current therapeutics, such as sexual dysfunction and weight gain. EXXUA, as a first-in-class selective serotonin 5HT1a receptor agonist, enters this market with a novel mechanism of action and a differentiated clinical profile, specifically addressing the issue of sexual side effects by demonstrating an incidence comparable to placebo, unlike many existing selective serotonin reuptake inhibitors (SSRIs). This positions EXXUA to potentially capture a meaningful share of the market by offering a new treatment option for the over 21 million Americans affected by MDD.

Comparison to Industry Standards

• EXXUA is highlighted as the only antidepressant acting on serotonin receptors that does not carry label warnings about the risk of sexual dysfunction, a common and problematic side effect associated with many existing MDD treatments, particularly Selective Serotonin Reuptake Inhibitors (SSRIs).
• Clinical trials involving over 5,000 patients demonstrated that the incidence of sexual side effects with EXXUA was comparable to placebo, setting it apart from many conventional antidepressants.
• Unlike some other antidepressants, EXXUA exhibits no significant adverse effects on weight, blood pressure, heart rate, or liver function, which are often concerns with other classes of MDD medications.
• EXXUA's mechanism of action as a selective serotonin 5HT1a receptor agonist differentiates it from SSRIs, which primarily inhibit serotonin reuptake, offering a new class of therapeutics in the MDD market.

Stakeholder Impact

• Shareholders: Expected to benefit from increased company value and potential revenue growth driven by the commercialization of EXXUA.
• Patients: Will gain access to a new, differentiated treatment option for Major Depressive Disorder (MDD) that addresses common side effects like sexual dysfunction.
• Physicians: Will have an important new tool in their "armamentarium" to manage MDD patients, particularly those who experience problematic side effects with current treatments.
• Employees: The launch of EXXUA will likely involve increased commercial efforts, potentially impacting sales and marketing teams.

Next Steps

• Aytu BioPharma anticipates launching EXXUA in the fourth calendar quarter of 2025.
• Aytu is actively preparing for the U.S. launch of EXXUA.
• The full text of the Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2025, with confidential portions redacted.

Key Dates

Recommendation

Keywords

Aytu BioPharma, EXXUA, gepirone, Major Depressive Disorder, MDD, antidepressant, pharmaceutical, commercialization agreement, FDA approval, mental health, CNS products, drug launch